Triple-Negative Breast Cancer Diagnosis: A Real Patient Case
Privacy note: This article is based on the real medical journey of a patient in Asia and is shared with her family’s consent. Her specific location and other demographic details have been kept private to respect her privacy.
Her pathology report contained the word “negative” several times. In ordinary life, negative may sound reassuring. In breast cancer testing, it can carry a very different meaning.
Her cancer tested negative for estrogen receptors, progesterone receptors, and HER2. Together, these findings identified a triple-negative breast cancer profile. A later blood test also found no clinically relevant harmful variants in the BRCA1 or BRCA2 genes.
These results did not mean that cancer was absent. They meant that several biological targets commonly used to treat other breast cancers were not present.
This real case shows how biopsy findings, lymph-node results, imaging, receptor testing, and genetic testing gradually formed a more complete understanding of a complex diagnosis.
The Biopsy and the First Answer
The available medical records begin with a breast biopsy performed to determine whether the abnormality was cancerous and what type of cancer was present.
The pathology report identified invasive carcinoma with lobular features in the right breast. The pathologist noted that it could represent lobular carcinoma or a cancer containing both ductal and lobular features.
This did not mean that the patient had several unrelated cancers. It described how the cancer cells appeared when examined under a microscope.
The word “invasive” meant that the cancer had grown beyond the structure where it began and entered the surrounding breast tissue. It did not, by itself, determine how far the cancer had spread through the body.
The tumor was provisionally classified as grade 2, with a reported score of 6 out of 9. Grade describes how abnormal the cancer cells appear under a microscope. It is different from stage, which describes the extent of the disease.
Cancer Was Found in the Lymph Nodes
Lymph nodes under both arms were also biopsied.
Cancer cells consistent with a breast origin were identified in the right and left axillary lymph nodes. This showed that the cancer was not limited to the original breast abnormality.
Lymph nodes are part of the lymphatic system. They are common places for breast cancer cells to travel because lymphatic vessels carry fluid from the breast to nearby nodes.
The lymph-node results were important, but they were not interpreted alone. Doctors also considered the breast findings, physical examination, PET/CT results, and the patient’s overall clinical condition.
Three Negative Results with an Important Meaning
Immunohistochemistry testing performed on the biopsy tissue examined three biomarkers that help guide breast cancer treatment. It showed that the cancer was negative for estrogen receptors and progesterone receptors, while HER2 received a score of 0 and was classified as negative.
- Estrogen receptor, or ER, was negative.
- Progesterone receptor, or PR, was negative.
- HER2 was negative, with a reported score of 0.
Because all three markers were negative, the cancer had a triple-negative breast cancer profile.
Triple-negative breast cancer is not three separate cancers. The name describes the absence of three commonly used treatment targets.
Hormone receptor-positive cancers may respond to hormone therapy. HER2-positive cancers may respond to medicines that specifically target the HER2 protein. When ER, PR, and HER2 are all negative, those particular treatment approaches are generally not expected to work.
This narrowed the range of targeted treatments available to the patient, but it did not mean that treatment was impossible.
Chemotherapy remains an important treatment for triple-negative breast cancer. Depending on the stage, previous treatment, additional biomarker results, and the patient’s overall health, other options may include immunotherapy, antibody-drug conjugates, radiation therapy, surgery, or other medicines.
The appropriate treatment cannot be determined from the words “triple-negative” alone. National Cancer Institute
A Cancer That Did Not Fit Every Common Pattern
Triple-negative breast cancer is a biomarker category rather than one single biological disease. Two patients can both have triple-negative results while their cancers behave differently.
This patient’s report also described lobular features and a Ki-67 level of approximately 10 to 15 percent.
Ki-67 is a marker used to estimate how many cancer cells are actively dividing. This result did not change the triple-negative classification. It was another part of the pathology picture that had to be considered with the tumor type, grade, imaging findings, and clinical course.
The combination made the case complex, but it should not be described as completely unique. Breast cancers can have overlapping features that do not fit one familiar pattern.
How the Biopsy and PET/CT Findings Supported the Stage 4 Diagnosis
The breast biopsy confirmed invasive carcinoma with lobular features in the right breast. Separate biopsies also identified cancer cells consistent with a breast origin in the axillary lymph nodes under both arms.
The PET/CT scan then helped assess the wider extent of the disease. It showed activity in the right breast and several lymph-node areas, including the axillary and right supraclavicular nodes. It also identified an area in the left femur with cortical change that was considered suspicious for metastatic bone involvement.
Small lung nodules were also visible, but they were too small to characterize reliably at that time.
These findings provided different but connected pieces of information. The breast biopsy confirmed the cancer type, the lymph-node biopsies confirmed that cancer was present beyond the original breast site, and the PET/CT raised concern that it had reached a distant bone. Collectively, these findings supported the stage 4 diagnosis communicated to the patient and her family.
Stage 4 breast cancer is also called metastatic breast cancer. It means that the cancer has spread from the breast to a distant part of the body. In this case, the suspicious finding in the left femur was particularly important because bone involvement represents distant spread. National Cancer Institute
The words “invasive” and “triple-negative” did not independently establish stage 4. The stage reflected the overall extent of the disease shown by the combined biopsy, lymph-node, imaging, and clinical findings.
Why BRCA1 and BRCA2 Were Tested
Triple-negative breast cancer can sometimes be associated with an inherited harmful variant in the BRCA1 gene. However, a triple-negative diagnosis does not automatically mean that a BRCA variant is present.
BRCA1 and BRCA2 are genes that normally help repair damaged DNA. Harmful inherited variants in these genes can increase the risk of breast, ovarian, and certain other cancers. They may also influence treatment decisions in some patients. National Cancer Institute
A blood sample was used for this patient’s BRCA1/2 full-gene analysis. Because the test examined DNA from blood, it was intended to look for inherited, or germline, variants.
The BRCA1/2 Result Was Negative
The final BRCA report stated:
“Negative report. No clinically relevant variants were detected.”
This meant that the test did not identify a clinically relevant harmful variant in BRCA1 or BRCA2.
It did not mean that the cancer diagnosis was negative. It also did not explain why the cancer developed.
A negative BRCA1/2 result does not rule out every possible inherited cancer-related variant. Other genes, including PALB2, TP53, PTEN, and CDH1, may be relevant in selected patients.
Whether broader genetic testing is appropriate depends on the person’s medical history, family history, ancestry, and the scope of the original test.
For this patient, the blood-test result did not establish eligibility for treatment based specifically on an inherited BRCA1 or BRCA2 variant. Treatment eligibility can also depend on the cancer setting, tumor testing, previous treatments, and other clinical findings.
Planning Treatment with Fewer Targets
By the time the initial results were considered together, the medical team was working with fewer biological treatment targets than are available for some other breast cancer subtypes.
Hormone therapy would not generally be expected to treat a tumor that was negative for both estrogen and progesterone receptors. HER2-targeted medicines would not generally be selected for a tumor reported as HER2 score 0. The germline BRCA1/2 test did not identify a harmful variant that could guide a BRCA-based treatment decision.
However, this did not mean that no treatment options remained.
Triple-negative breast cancer can still be treated. In stage 4 disease, treatment goals may include slowing cancer growth, reducing symptoms, maintaining quality of life, and helping the patient live as comfortably and fully as possible.
The available treatment choices depend on the disease extent, additional biomarkers, previous treatment, overall health, and how the cancer responds over time.
The difficulty was not a complete absence of treatment. The difficulty was that treatment had to proceed without several of the targets available in other breast cancer subtypes.
What These Findings Help Us Understand
Every negative result in this case had a different meaning.
- A negative receptor result meant that a particular treatment target was not present.
- A negative BRCA1/2 blood test meant that no clinically relevant harmful variant was identified in those two genes.
- Neither result meant that the cancer was absent. Neither result could explain the complete diagnosis on its own.
- “Invasive” described how the cancer had grown into the surrounding breast tissue.
- “Lobular features” described how the cancer cells appeared under a microscope.
- “Grade 2” described the degree of abnormality seen in the tissue.
- “Triple-negative” described the absence of ER, PR, and HER2 treatment targets.
- “BRCA-negative” described the reported germline genetic-test result.
- “Stage 4” described the extent of the disease, as supported by the combined biopsy, lymph-node, PET/CT, and clinical findings.
Together, these findings provided a more complete understanding of the diagnosis than any individual result could provide.
If You Are Supporting Someone through This
Hearing several negative results can be confusing, especially when negative ordinarily sounds like good news.
A negative receptor result is not the same as a negative genetic test. A negative BRCA test is not the same as a negative biopsy. Each result only makes sense when you know exactly what was tested.
You do not need to understand an entire pathology report in one sitting. Four questions can provide a helpful starting point.
- What exact type of cancer was identified?
- What are the ER, PR, and HER2 results?
- What have the imaging and lymph-node findings shown?
- Were genetic or additional biomarker tests performed?
Write the answers down. A complicated diagnosis can become easier to understand and discuss when the information is clearly organized.
Key Takeaways
- This real case involved invasive breast carcinoma with lobular features in the right breast.
- “Invasive” meant that the cancer had grown into the surrounding breast tissue. It did not independently establish that the cancer was stage 4.
- The tumor was provisionally classified as grade 2, with a reported score of 6 out of 9.
- Cancer cells consistent with a breast origin were identified in axillary lymph nodes under both arms.
- Biomarker testing performed on the biopsy tissue showed that the tumor was ER-negative, PR-negative, and HER2-negative, with a HER2 score of 0.
- These three negative biomarker results established the triple-negative breast cancer profile.
- The reported Ki-67 level was approximately 10 to 15 percent. This finding provided information about cancer-cell division but did not change the triple-negative classification.
- The PET/CT showed activity in the breast and several lymph-node areas. It also identified a left femur finding that was suspicious for metastatic bone involvement.
- The breast biopsy, lymph-node biopsies, PET/CT, and complete clinical findings collectively supported the stage 4 diagnosis.
- Stage 4 breast cancer means that the cancer has reached a distant part of the body. It was not determined by the words “invasive” or “triple-negative” alone.
- The absence of ER, PR, and HER2 narrowed the commonly available hormone-based and HER2-targeted treatment options.
- The BRCA1/2 blood test found no clinically relevant harmful variants in those two genes.
- A negative BRCA1/2 result does not mean that the cancer was negative, explain why it developed, or rule out every hereditary cancer-related gene.
- Triple-negative and BRCA-negative results do not mean that no treatment options remain. Treatment planning depends on the disease extent, additional biomarkers, previous treatment, overall health, and response over time.
Related Reading
Benign, Malignant, Positive and Negative Biopsy Results
References
National Cancer Institute. (n.d.). BRCA gene changes: Cancer risk and genetic testing. https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet
National Cancer Institute. (n.d.). How is triple-negative breast cancer treated? https://www.cancer.gov/types/breast/treatment/triple-negative-breast-cancer
National Cancer Institute. (n.d.). Understanding breast cancer staging. https://www.cancer.gov/types/breast/stages
Medical Disclaimer
This source-supported article provides reliable information to strengthen your understanding of triple-negative breast cancer and complement personalized medical guidance from a qualified healthcare professional who understands your individual findings and history.